PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
February 28, 2026CureusOpen Access

Obinutuzumab Treatment in Rituximab- and Bortezomib-Resistant Phospholipase A2 Receptor Antibody-Positive Membranous Nephropathy

View Full Paper
Ask AI
Bookmark
Share

Authors

UYUygar YildirimSOSultan OzkurtAYAhmet Ugur Yalcin

Discussion

Loading...

Member takes

Overview

Case report demonstrates improved outcomes in membranous nephropathy after obinutuzumab treatment, suggesting new therapeutic possibilities.

Key Points

  • To evaluate the effectiveness of obinutuzumab in a case of rituximab- and bortezomib-resistant membranous nephropathy.
  • Reported case of a 54-year-old man with PLA2R antibody-positive primary MN
  • Administered obinutuzumab after failure of multiple immunosuppressive therapies including rituximab and bortezomib
  • Monitored clinical improvement and laboratory parameters post-treatment
  • Rapid and sustained clinical improvement observed after obinutuzumab treatment
  • Substantial reduction in proteinuria and normalization of serum albumin
  • Recovery of renal function noted after treatment

Cite This Study

Yildirim et al. (2026) studied this question.

synapsesocial.com/papers/69a286850a974eb0d3c018e7https://doi.org/10.7759/cureus.104285
View Full Paper
Ask AI
Bookmark
Share